Qritive
Qritive is a Singapore-based AI healthcare company that builds deep learning-powered digital pathology software for cancer diagnosis. Its Pantheon platform and QAi modules help hospitals, pathology laboratories, and diagnostic chains automate detection, grading, and reporting for prostate, colon, and lymph node cancers.
- Company typePrivate
- Founded2017
- HeadquartersSingapore, Singapore
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Qritive does
Qritive Pte. Ltd. is a Singapore-incorporated healthcare AI company founded in 2017 that develops deep learning-powered digital pathology solutions for cancer diagnosis. Its flagship platform, Pantheon™, is an AI-powered image management workbench that digitizes and streamlines the end-to-end pathology workflow, from whole-slide image viewing and case management to AI-assisted diagnosis and structured reporting. Qritive's AI module portfolio includes QAi Prostate Grade (prostate cancer grading aligned to ISUP Grade Group classifications), QAi Lymph Node Dx (segmentation-based detection of micro- and macrometastases across breast, colon, and gastric tumors), AI-Assisted Ki-67 Scoring (biomarker analysis for sarcoma), and biomarker analysis modules. The underlying technology combines region-based convolutional networks (Faster R-CNN with ResNet-50/101 backbone) for glandular segmentation with classical machine learning classifiers for composite diagnostic decisions, trained on a corpus of 400,000+ pathology images.
The company operates a B2B enterprise subscription model, monetizing AI diagnostic software modules, Pantheon platform licensing, and related Software-as-a-Medical-Device (SaMD) services through annual contracts to hospitals, pathology laboratories, and diagnostic chain networks. Pricing is quote-based and tailored to institutional scale, deployment requirements, and regulatory certifications, with annual billing. Go-to-market is primarily direct enterprise field sales targeting pathologists and laboratory decision-makers, supplemented by active presence at major pathology conferences (USCAP, ECDP, Medlab Middle East), peer-reviewed scientific publications, strategic partnerships with Roche, M42, Sectra, and Tribun Health, and participation in accelerator programs (MedTech Innovator Asia Pacific 2024, Cedars-Sinai Accelerator). The company holds CE marking, Singapore HSA Class C IVD registration, Abu Dhabi Department of Health approval, ISO 13485:2016, and ISO/IEC 27001:2022 certifications, and operates across Singapore, India, the United States, the UAE, Japan, and Europe with an 11-50 person team led by CEO and co-founder Aneesh Sathe and CTO and co-founder Kaveh Taghipour.
Qritive has raised approximately $9 million in disclosed funding, most recently a $7.5 million Series A in January 2023 led by MassMutual Ventures with SEEDS Capital and Exfinity Venture Partners. Named enterprise customers include Dr Lal PathLabs, Metropolis Healthcare, Rajiv Gandhi Cancer Institute and Research Centre, Cleveland Clinic Abu Dhabi, and M42's National Reference Laboratory. The company maintains a branded education platform, Qritive Academy, and pursues open-ecosystem integration through Sectra Amplifier Marketplace and Tribun Health's CaloPix Connect API alongside technology partnerships with Philips, AWS, NVIDIA, Dell, NTT, Corista, and Motic.
Qritive firmographics
Firmographics- Name
- Qritive
- Legal name
- Qritive Pte. Ltd.
- Website
- https://qritive.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Qritive is a Singapore-based AI healthcare company that builds deep learning-powered digital pathology software for cancer diagnosis. Its Pantheon platform and QAi modules help hospitals, pathology laboratories, and diagnostic chains automate detection, grading, and reporting for prostate, colon, and lymph node cancers.
- Ownership category
- akta.pro rank
Qritive industry classification
Industry- Product category
- Digital Pathology Software
- NAICS
- Software Publishers (51321), Software Publishers (5132)
- SIC
- Services-Prepackaged Software (7372), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG), Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ), Medical Imaging AI (HDAAAEAH)
Keywords
Where Qritive is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices4 records
Markets served
Qritive business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- AI Diagnostic Software Modules: Revenue from AI-powered diagnostic algorithms and modules deployed to healthcare institutions. Modules include QAi Prostate Grade, QAi Lymph Node Dx, and other cancer detection solutions sold to pathology labs and hospitals.
- Pantheon Platform Licensing: Licensing of Pantheon image management system to pathology laboratories and healthcare institutions for digital pathology workflow management.
- Enterprise Software Services: Services related to AI-based pathology diagnostic solutions developed as Software as a Medical Device (SaMD), including implementation and support.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise licensing model for healthcare institutions |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
Qritive product offering
Product offeringCore offering
Qritive develops and sells AI-powered digital pathology software — primarily the Pantheon™ image management platform and a suite of AI diagnostic modules (QAi Prostate Grade, QAi Lymph Node Dx, AI-Assisted Ki-67 Scoring, biomarker analysis) — to hospitals, pathology laboratories, and diagnostic chains for faster and more accurate cancer diagnosis. The platform and modules are sold as Software as a Medical Device (SaMD) under annual enterprise subscriptions with regulatory clearances including CE marking, Singapore HSA Class C IVD, and Abu Dhabi Department of Health approval.
Product overview
Qritive offers an AI-powered digital pathology ecosystem centered on Pantheon™, an image management platform that digitizes and streamlines the entire pathology workflow. The portfolio includes AI diagnostic modules — QAi Prostate (including QAi Prostate Grade), QAi Lymph Node Dx, AI-Assisted Ki-67 Scoring, and other cancer diagnostic modules — all hardware-agnostic and designed to integrate with Pantheon™ or other image management systems. Qritive Academy provides supplementary pathology education. The platform is CE-marked, HSA-registered, and available globally through partnerships including Roche, M42, and Dr Lal PathLabs.
Differentiator
Problem solved
Functional benefit
Brands
- Pantheon™: AI-powered pathology workbench and image management platform for digitizing and streamlining the entire pathology workflow, from slide viewing and case management to AI-supported diagnosis and structured reporting. CE-marked and HSA-registered.
- QAi Prostate
- QAi Suite
- Qritive Academy
Products and services
- Pantheon™ Image Management System AI-powered pathology workbench and image management platform that digitizes and streamlines the entire pathology workflow — from slide viewing, case management, AI-supported diagnosis to structured reporting. Vendor-agnostic, cloud-ready, supports all major whole-slide image formats, and integrates with hospital systems, LIS, and external AI modules. CE-marked and HSA-registered.
- QAi Prostate (QAi Prostate Grade) AI-powered diagnostic module that supports pathologists in achieving faster, more accurate prostate cancer diagnoses with greater confidence in reporting, including Gleason grading support. The QAi Prostate Grade module has received Class C IVD approval from Singapore HSA and regulatory approval from Abu Dhabi's Department of Health.
- QAi Lymph Node Dx AI-powered module for detecting lymph node metastasis across multiple cancer types including breast, colon, and gastric tumors. Uses a segmentation-based deep learning approach to detect both micro- and macrometastases. Deployed at Dr Lal PathLabs in clinical workflows.
- AI-Assisted Ki-67 Scoring Computer vision-based AI module for evaluating Ki-67 proliferative index on IHC-stained whole-slide images, applied to sarcoma cases to reduce inter-observer variability and improve diagnostic reproducibility.
- Qritive Academy Dedicated online platform for continuous learning and professional development in pathology, offering both foundational and advanced content tailored to diagnostic needs to make high-quality education accessible to pathologists worldwide.
Quantifiable outcome
- Achieved AUC of 0.917 with 97.4% sensitivity for colorectal cancer detection
- +2 more outcomes
Companies that use Qritive
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
Qritive technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability5 records
Feature6 records
Qritive partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered strategic and core.
- M42's National Reference LaboratorystrategicM42's National Reference Laboratory introduced AI-powered prostate cancer diagnostics in the UAE through partnership with Qritive, integrated into Cleveland Clinic Abu Dhabi's diagnostic workflow. Partnership supports UAE's healthcare innovation goals under Vision 2031.
- Tribun HealthcoreQritive's AI solutions available through Tribun Health's CaloPix Connect open API, enabling integration of third-party AI tools into digital pathology workflows. Qritive is listed among approved AI providers including Aiforia, DeepPath, Primaa, Owkin, and Ibex.
- RochestrategicStrategic partnership announced September 2024 to redefine global cancer diagnostics with AI. Qritive featured as partner in Roche's digital pathology ecosystem.
- SectracoreFeatured at Sectra Amplifier Marketplace, enabling integration of Qritive's AI solutions with Sectra's enterprise imaging platform for digital pathology.
- Dr. Lal PathLabsstrategicDr. Lal PathLabs selected Qritive's QAi Lymph Node Dx to enhance capabilities in detecting lymph node metastasis as part of routine clinical workflows. Collaborative study presented at USCAP 2025.
- Rajiv Gandhi Cancer Institute and Research CentrestrategicClinical collaboration deploying QAi Prostate Grade module at RGCIRC in India, supported by MeitY-nasscom Center of Excellence. Real-world impact study demonstrating AI enhancement of prostate cancer diagnosis.
- Nagasaki University Graduate School of Biomedical SciencesstrategicCollaborative study with Dr. Kris Lami evaluating deep learning AI algorithm for detecting lymph node metastasis across multiple cancer types, presented at ECDP 2025.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
Qritive competitors and assessment
Company assessmentDirect peers
- PathAI: PathAI develops AI-powered pathology tools for cancer diagnosis and biomarker analysis, directly competing with Qritive's QAi Prostate Grade and Lymph Node Dx modules in the same hospital and reference-lab customer segment.
- Paige.AI: Paige builds clinical-grade AI applications for pathology including prostate, breast, and other cancer detection, overlapping directly with Qritive's cancer-specific diagnostic modules and target pathologist buyer.
- Ibex Medical Analytics: Ibex provides an AI platform for cancer diagnostics in pathology (Galen, Second Read), competing head-to-head with Qritive's QAi suite for the same pathology lab and hospital customers globally.
- Aiforia: Aiforia offers deep learning AI solutions for image-based diagnostics including pathology, with comparable prostate and other tissue analysis modules; listed alongside Qritive on Tribun Health's CaloPix Connect AI marketplace.
- Owkin: Owkin applies AI to pathology and oncology, including digital pathology AI tools; co-listed with Qritive as an approved AI provider on Tribun Health's CaloPix Connect platform, making it a direct competitor in third-party pathology AI.
- Proscia: Proscia offers a digital pathology platform (Concentriq) with embedded AI for cancer diagnostics, overlapping with Qritive's Pantheon image management and AI module offering for enterprise pathology customers.
Emerging players
- Primaa: Primaa develops AI algorithms for dermatopathology and other pathology use cases, also co-listed on Tribun Health's CaloPix Connect marketplace alongside Qritive's modules.
- DeepPath: DeepPath provides AI-based pathology image analysis, also featured on Tribun Health's CaloPix Connect as a comparable third-party AI pathology provider to Qritive.
Broad incumbents
- Lunit: Lunit is a Korean AI medtech company with pathology and radiology AI products (including Lunit SCOPE), operating more broadly across cancer diagnostics than Qritive but with overlapping clinical buyers and use cases.
- Roche (Roche Digital Pathology): Roche operates a large digital pathology platform (uPath/Roche Digital Pathology) and is simultaneously a Qritive strategic partner and a competitor offering native AI; comparable as a broad incumbent with overlapping enterprise pathology footprint.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Qritive social profiles
Digital presenceQritive compliance and trust
Trust signalCompliance8 records
Qritive financial estimates
Financial estimateRevenue estimate
Valuation estimate
Qritive leadership team
Management profileNumber of profiles
Profiles4 records
Qritive funding detail
Funding detailFunding overview
Funding rounds8 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Qritive M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Qritive
What does Qritive do?
Qritive develops and sells AI-powered digital pathology software — primarily the Pantheon™ image management platform and a suite of AI diagnostic modules (QAi Prostate Grade, QAi Lymph Node Dx, AI-Assisted Ki-67 Scoring, biomarker analysis) — to hospitals, pathology laboratories, and diagnostic chains for faster and more accurate cancer diagnosis. The platform and modules are sold as Software as a Medical Device (SaMD) under annual enterprise subscriptions with regulatory clearances including CE marking, Singapore HSA Class C IVD, and Abu Dhabi Department of Health approval.
Is Qritive a public or private company?
Qritive is a private company. It is classified as venture growth investor backed and is currently operating.
When was Qritive founded?
Qritive was founded in 2017. It employs 11 to 50 people.
Where is Qritive based?
Qritive is headquartered in Singapore, Singapore, in the Asia region.
How does Qritive make money?
Three revenue lines are on record. AI Diagnostic Software Modules are the primary driver. The others are pantheon Platform Licensing and enterprise Software Services.
Who are Qritive's main competitors?
Direct peers on record are PathAI, Paige.AI, Ibex Medical Analytics, Aiforia, Owkin and Proscia. Emerging players are Primaa and DeepPath. Broad incumbents are Lunit and Roche (Roche Digital Pathology).
Does Qritive have an API?
No public API is recorded for Qritive.
What industry is Qritive in?
Qritive's product category is Digital Pathology Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage). Its NAICS code is 51321 and its SIC code is 7372.